CDT Provides Capital Update and Confirms No Nasdaq Deficiencies
CDT Equity (CDT) reported updated capital figures and confirmed its Nasdaq compliance status as of late August 2026.
Rhea-AI Summary
CDT Equity (CDT) reported updated capital figures and confirmed its Nasdaq compliance status as of late August 2026.
After recent share issuances and exercises of pre-funded warrants, CDT had 13,693,866 shares of common stock issued and outstanding as of August 31, 2026. Based on that day’s closing share price, the company’s market capitalization was approximately $23.0 million. CDT’s stockholders’ equity, reported in its Form 10-Q for the quarter ended June 30, 2026, was approximately $103 million. The company also stated that, following these issuances and related corporate actions, it no longer has any outstanding deficiencies with The Nasdaq Stock Market.
Positive
- Shares outstanding updated to 13,693,866 as of August 31, 2026
- Implied market capitalization of approximately $23.0 million as of August 31, 2026
- Reported stockholders’ equity of approximately $103 million as of June 30, 2026
- Company confirms it has no outstanding Nasdaq deficiencies
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Sep 01 | Leadership change | Positive | -16.7% | Co-founder James Bligh became CEO as Andrew Regan moved to Sarborg. |
| Aug 28 | IP portfolio update | Positive | -10.1% | CDT reported enhanced solid-form stability, solubility, and manufacturability within its portfolio. |
| Aug 25 | Strategic investment | Positive | -18.5% | CDT entered a SAFE investment providing exposure to Pep'd's peptide business. |
| Aug 03 | Stake increase | Positive | -2.2% | CDT agreed to increase its Sarborg stake to 22.7% through pre-funded warrants. |
| Jul 20 | Patent filing | Positive | +13.8% | Sarborg filed a patent application extending its platform into sugarcane interventions. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Four of five recent announcements were followed by declines, with only the July 20 patent announcement followed by a positive reaction.
Key Terms
pre-funded warrants financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announced that, following the recent issuance of shares and the exercise of pre-funded warrants, the Company had 13,693,866 shares of Common Stock issued and outstanding as of August 31, 2026. Based on the closing price of CDT’s Common Stock on August 31, 2026, the Company had a market capitalisation of approximately
CDT’s stockholders’ equity, as reported in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, was approximately
About CDT Equity Inc.
CDT Equity Inc. (NASDAQ: CDT) is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. Looking ahead, CDT are committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding CDT's future results of operations and financial position, CDT's business strategy, prospective product candidates, product approvals, research and development cost timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the effect that the reverse stock split may have on the price of the Company’s common stock; the ability or inability to maintain the listing of CDT's securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that CDT's product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that CDT may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties identified in other filings made by CDT with the U.S. Securities and Exchange Commission. Moreover, CDT operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond CDT's control, you should not rely on these forward-looking statements as predictions of future events.
Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, CDT assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. CDT gives no assurance that it will achieve its expectations.
Investors
CDT Equity Inc.
Info@cdtequity.com
